Global and United States Primary Sclerosing Cholangitis Treatment Market Report & Forecast 2022-2028

Global and United States Primary Sclerosing Cholangitis Treatment Market Report & Forecast 2022-2028

Table of Contents
1 Study Coverage
1.1 Primary Sclerosing Cholangitis Treatment Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Primary Sclerosing Cholangitis Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size for the Year 2017-2028
1.2.2 Global Primary Sclerosing Cholangitis Treatment Market Size for the Year 2017-2028
1.3 Primary Sclerosing Cholangitis Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Primary Sclerosing Cholangitis Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Primary Sclerosing Cholangitis Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Primary Sclerosing Cholangitis Treatment Market Dynamics
1.4.1 Primary Sclerosing Cholangitis Treatment Industry Trends
1.4.2 Primary Sclerosing Cholangitis Treatment Market Drivers
1.4.3 Primary Sclerosing Cholangitis Treatment Market Challenges
1.4.4 Primary Sclerosing Cholangitis Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Primary Sclerosing Cholangitis Treatment by Type
2.1 Primary Sclerosing Cholangitis Treatment Market Segment by Type
2.1.1 Liver Transplantation Operation
2.1.2 UDCA Drugs
2.1.3 PSC Drugs
2.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017, 2022 & 2028)
2.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028)
2.4 United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017, 2022 & 2028)
2.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028)
3 Primary Sclerosing Cholangitis Treatment by Application
3.1 Primary Sclerosing Cholangitis Treatment Market Segment by Application
3.1.1 Hospital
3.1.2 Clinics
3.1.3 Other
3.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017, 2022 & 2028)
3.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028)
3.4 United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017, 2022 & 2028)
3.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028)
4 Global Primary Sclerosing Cholangitis Treatment Competitor Landscape by Company
4.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Company
4.1.1 Top Global Primary Sclerosing Cholangitis Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue by Player (2017-2022)
4.2 Global Primary Sclerosing Cholangitis Treatment Concentration Ratio (CR)
4.2.1 Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Primary Sclerosing Cholangitis Treatment in 2021
4.2.3 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Primary Sclerosing Cholangitis Treatment Headquarters, Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Primary Sclerosing Cholangitis Treatment Headquarters and Area Served
4.3.2 Global Primary Sclerosing Cholangitis Treatment Companies Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Primary Sclerosing Cholangitis Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Company
4.5.1 Top Primary Sclerosing Cholangitis Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Primary Sclerosing Cholangitis Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Primary Sclerosing Cholangitis Treatment Market Size by Region
5.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2028)
5.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017-2022
5.2.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Allergan
7.1.1 Allergan Company Details
7.1.2 Allergan Business Overview
7.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
7.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.1.5 Allergan Recent Development
7.2 Glenmark
7.2.1 Glenmark Company Details
7.2.2 Glenmark Business Overview
7.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
7.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.2.5 Glenmark Recent Development
7.3 Impax Laboratories
7.3.1 Impax Laboratories Company Details
7.3.2 Impax Laboratories Business Overview
7.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
7.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.3.5 Impax Laboratories Recent Development
7.4 Mylan
7.4.1 Mylan Company Details
7.4.2 Mylan Business Overview
7.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
7.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.4.5 Mylan Recent Development
7.5 Teva Pharmaceuticals
7.5.1 Teva Pharmaceuticals Company Details
7.5.2 Teva Pharmaceuticals Business Overview
7.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
7.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.5.5 Teva Pharmaceuticals Recent Development
7.6 Dr. Falk Pharma
7.6.1 Dr. Falk Pharma Company Details
7.6.2 Dr. Falk Pharma Business Overview
7.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
7.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.6.5 Dr. Falk Pharma Recent Development
7.7 Daewoong Pharmaceutical
7.7.1 Daewoong Pharmaceutical Company Details
7.7.2 Daewoong Pharmaceutical Business Overview
7.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
7.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.7.5 Daewoong Pharmaceutical Recent Development
7.8 Epic Pharma
7.8.1 Epic Pharma Company Details
7.8.2 Epic Pharma Business Overview
7.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
7.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.8.5 Epic Pharma Recent Development
7.9 Mitsubishi Tanabe Pharma
7.9.1 Mitsubishi Tanabe Pharma Company Details
7.9.2 Mitsubishi Tanabe Pharma Business Overview
7.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
7.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.9.5 Mitsubishi Tanabe Pharma Recent Development
7.10 Lannett
7.10.1 Lannett Company Details
7.10.2 Lannett Business Overview
7.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
7.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.10.5 Lannett Recent Development
7.11 Bruschettini
7.11.1 Bruschettini Company Details
7.11.2 Bruschettini Business Overview
7.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
7.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.11.5 Bruschettini Recent Development
7.12 Shanghai Pharma
7.12.1 Shanghai Pharma Company Details
7.12.2 Shanghai Pharma Business Overview
7.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
7.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.12.5 Shanghai Pharma Recent Development
7.13 Grindeks
7.13.1 Grindeks Company Details
7.13.2 Grindeks Business Overview
7.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
7.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.13.5 Grindeks Recent Development
7.14 Acorda Therapeutics
7.14.1 Acorda Therapeutics Company Details
7.14.2 Acorda Therapeutics Business Overview
7.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
7.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.14.5 Acorda Therapeutics Recent Development
7.15 Gilead Sciences
7.15.1 Gilead Sciences Company Details
7.15.2 Gilead Sciences Business Overview
7.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
7.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.15.5 Gilead Sciences Recent Development
7.16 Intercept Pharmaceuticals
7.16.1 Intercept Pharmaceuticals Company Details
7.16.2 Intercept Pharmaceuticals Business Overview
7.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
7.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.16.5 Intercept Pharmaceuticals Recent Development
7.17 Shire Plc
7.17.1 Shire Plc Company Details
7.17.2 Shire Plc Business Overview
7.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
7.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.17.5 Shire Plc Recent Development
7.18 NGM Biopharmaceuticals
7.18.1 NGM Biopharmaceuticals Company Details
7.18.2 NGM Biopharmaceuticals Business Overview
7.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
7.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.18.5 NGM Biopharmaceuticals Recent Development
7.19 Conatus Pharmaceuticals
7.19.1 Conatus Pharmaceuticals Company Details
7.19.2 Conatus Pharmaceuticals Business Overview
7.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
7.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.19.5 Conatus Pharmaceuticals Recent Development
7.20 Durect Corporation
7.20.1 Durect Corporation Company Details
7.20.2 Durect Corporation Business Overview
7.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
7.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.20.5 Durect Corporation Recent Development
7.21 Sirnaomics
7.21.1 Sirnaomics Company Details
7.21.2 Sirnaomics Business Overview
7.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
7.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.21.5 Sirnaomics Recent Development
7.22 Shenzhen HighTide Biopharmaceuticals
7.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
7.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
7.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
7.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
7.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Primary Sclerosing Cholangitis Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Primary Sclerosing Cholangitis Treatment Market Trends
Table 3. Primary Sclerosing Cholangitis Treatment Market Drivers
Table 4. Primary Sclerosing Cholangitis Treatment Market Challenges
Table 5. Primary Sclerosing Cholangitis Treatment Market Restraints
Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Primary Sclerosing Cholangitis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Primary Sclerosing Cholangitis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Primary Sclerosing Cholangitis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Primary Sclerosing Cholangitis Treatment Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Primary Sclerosing Cholangitis Treatment Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Player, 2017-2022
Table 13. Global Primary Sclerosing Cholangitis Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021)
Table 15. Top Players of Primary Sclerosing Cholangitis Treatment in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Primary Sclerosing Cholangitis Treatment Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Primary Sclerosing Cholangitis Treatment Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Primary Sclerosing Cholangitis Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Primary Sclerosing Cholangitis Treatment Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Primary Sclerosing Cholangitis Treatment Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Allergan Company Details
Table 31. Allergan Business Overview
Table 32. Allergan Primary Sclerosing Cholangitis Treatment Product
Table 33. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 34. Allergan Recent Development
Table 35. Glenmark Company Details
Table 36. Glenmark Business Overview
Table 37. Glenmark Primary Sclerosing Cholangitis Treatment Product
Table 38. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 39. Glenmark Recent Development
Table 40. Impax Laboratories Company Details
Table 41. Impax Laboratories Business Overview
Table 42. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
Table 43. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 44. Impax Laboratories Recent Development
Table 45. Mylan Company Details
Table 46. Mylan Business Overview
Table 47. Mylan Primary Sclerosing Cholangitis Treatment Product
Table 48. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 49. Mylan Recent Development
Table 50. Teva Pharmaceuticals Company Details
Table 51. Teva Pharmaceuticals Business Overview
Table 52. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 53. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 54. Teva Pharmaceuticals Recent Development
Table 55. Dr. Falk Pharma Company Details
Table 56. Dr. Falk Pharma Business Overview
Table 57. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
Table 58. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 59. Dr. Falk Pharma Recent Development
Table 60. Daewoong Pharmaceutical Company Details
Table 61. Daewoong Pharmaceutical Business Overview
Table 62. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
Table 63. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 64. Daewoong Pharmaceutical Recent Development
Table 65. Epic Pharma Company Details
Table 66. Epic Pharma Business Overview
Table 67. Epic Pharma Primary Sclerosing Cholangitis Treatment Product
Table 68. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 69. Epic Pharma Recent Development
Table 70. Mitsubishi Tanabe Pharma Company Details
Table 71. Mitsubishi Tanabe Pharma Business Overview
Table 72. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
Table 73. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 74. Mitsubishi Tanabe Pharma Recent Development
Table 75. Lannett Company Details
Table 76. Lannett Business Overview
Table 77. Lannett Primary Sclerosing Cholangitis Treatment Product
Table 78. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 79. Lannett Recent Development
Table 80. Bruschettini Company Details
Table 81. Bruschettini Business Overview
Table 82. Bruschettini Primary Sclerosing Cholangitis Treatment Product
Table 83. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 84. Bruschettini Recent Development
Table 85. Shanghai Pharma Company Details
Table 86. Shanghai Pharma Business Overview
Table 87. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product
Table 88. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 89. Shanghai Pharma Recent Development
Table 90. Grindeks Company Details
Table 91. Grindeks Business Overview
Table 92. Grindeks Primary Sclerosing Cholangitis Treatment Product
Table 93. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 94. Grindeks Recent Development
Table 95. Acorda Therapeutics Company Details
Table 96. Acorda Therapeutics Business Overview
Table 97. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product
Table 98. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 99. Acorda Therapeutics Recent Development
Table 100. Gilead Sciences Company Details
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product
Table 103. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 104. Gilead Sciences Recent Development
Table 105. Intercept Pharmaceuticals Company Details
Table 106. Intercept Pharmaceuticals Business Overview
Table 107. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 108. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 109. Intercept Pharmaceuticals Recent Development
Table 110. Shire Plc Company Details
Table 111. Shire Plc Business Overview
Table 112. Shire Plc Primary Sclerosing Cholangitis Treatment Product
Table 113. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 114. Shire Plc Recent Development
Table 115. NGM Biopharmaceuticals Company Details
Table 116. NGM Biopharmaceuticals Business Overview
Table 117. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 118. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 119. NGM Biopharmaceuticals Recent Development
Table 120. Conatus Pharmaceuticals Company Details
Table 121. Conatus Pharmaceuticals Business Overview
Table 122. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 123. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 124. Conatus Pharmaceuticals Recent Development
Table 125. Durect Corporation Company Details
Table 126. Durect Corporation Business Overview
Table 127. Durect Corporation Primary Sclerosing Cholangitis Treatment Product
Table 128. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 129. Durect Corporation Recent Development
Table 130. Sirnaomics Company Details
Table 131. Sirnaomics Business Overview
Table 132. Sirnaomics Primary Sclerosing Cholangitis Treatment Product
Table 133. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 134. Sirnaomics Recent Development
Table 135. Shenzhen HighTide Biopharmaceuticals Company Details
Table 136. Shenzhen HighTide Biopharmaceuticals Business Overview
Table 137. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 138. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 139. Shenzhen HighTide Biopharmaceuticals Recent Development
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Sclerosing Cholangitis Treatment Product Picture
Figure 2. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Primary Sclerosing Cholangitis Treatment Market Size 2017-2028 (US$ Million)
Figure 4. United States Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Primary Sclerosing Cholangitis Treatment Market Size 2017-2028 (US$ Million)
Figure 6. United States Primary Sclerosing Cholangitis Treatment Market Share in Global 2017-2028
Figure 7. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 8. Product Picture of Liver Transplantation Operation
Figure 9. Product Picture of UDCA Drugs
Figure 10. Product Picture of PSC Drugs
Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Share by Type in 2022 & 2028
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) & (US$ Million)
Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
Figure 14. United States Primary Sclerosing Cholangitis Treatment Market Share by Type in 2022 & 2028
Figure 15. United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) & (US$ Million)
Figure 16. United States Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
Figure 17. Product Picture of Hospital
Figure 18. Product Picture of Clinics
Figure 19. Product Picture of Other
Figure 20. Global Primary Sclerosing Cholangitis Treatment Market Share by Application in 2022 & 2028
Figure 21. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) & (US$ Million)
Figure 22. Global Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
Figure 23. United States Primary Sclerosing Cholangitis Treatment Market Share by Application in 2022 & 2028
Figure 24. United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) & (US$ Million)
Figure 25. United States Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
Figure 26. North America Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 27. U.S. Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 28. Canada Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 29. Europe Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 30. Germany Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. France Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. U.K. Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. Italy Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. Russia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 36. China Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Japan Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. South Korea Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. India Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. Australia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. Taiwan Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Indonesia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Thailand Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Malaysia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Philippines Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Latin America Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 47. Mexico Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Brazil Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Argentina Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 51. Turkey Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. U.A.E Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 55. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 56. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 57. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 58. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 59. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 60. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 61. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 62. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 63. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 64. Bruschettini Revenue

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs